{"organizations": [], "uuid": "a4097c1e171ce1d08c71197afafff9fd0abad0ac", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/markets/europe", "section_title": "European Stock Market News | Reuters.com", "url": "https://www.reuters.com/article/brief-cosmo-pharmaceuticals-aemcolo-nda/brief-cosmo-pharmaceuticals-aemcolo-nda-accepted-by-fda-idUSASC0A32J", "country": "US", "domain_rank": 408, "title": "BRIEF-Cosmo Pharmaceuticals' Aemcolo NDA Accepted by FDA", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.068, "site_type": "news", "published": "2018-05-21T23:03:00.000+03:00", "replies_count": 0, "uuid": "a4097c1e171ce1d08c71197afafff9fd0abad0ac"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-cosmo-pharmaceuticals-aemcolo-nda/brief-cosmo-pharmaceuticals-aemcolo-nda-accepted-by-fda-idUSASC0A32J", "ord_in_thread": 0, "title": "BRIEF-Cosmo Pharmaceuticals' Aemcolo NDA Accepted by FDA", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "cosmo pharmaceuticals nv", "sentiment": "negative"}, {"name": "nda", "sentiment": "negative"}, {"name": "brief-cosmo pharmaceuticals", "sentiment": "negative"}, {"name": "aries pharmaceuticals", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 21 (Reuters) - Cosmo Pharmaceuticals NV:\n* FDA ACCEPTS NEW DRUG APPLICATION FOR AEMCOLO (RIFAMYCIN SV MMXÂ®) AND SETS PDUFA DATE FOR NOVEMBER 16, 2018\n* COSMO PHARMACEUTICALS NV - UPON FDA APPROVAL OF AEMCOLO, ARIES PHARMACEUTICALS TO LEAD U.S. COMMERCIAL EFFORTS Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-21T23:03:00.000+03:00", "crawled": "2018-05-22T02:24:51.019+03:00", "highlightTitle": ""}